Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]

Conclusion
First-line nivolumab monotherapy demonstrated a tolerable safety profile and durable responses in first-line advanced NSCLC.

Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Gettinger, Rizvi, Chow, Borghaei, Brahmer, Ready, Gerber, Shepherd, Antonia, Goldman, Juergens, Laurie, Nathan, Shen, Harbison, Hellmann Tags: Chemotherapy Thoracic Oncology Source Type: research